SVB Leerink Downgrades Halozyme Therapeutics (HALO) to Market Perform

March 16, 2023 7:56 AM EDT Send to a Friend
SVB Leerink analyst David Risinger downgraded Halozyme Therapeutics (NASDAQ: HALO) from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login